SPRO · Insider Trading
Spero Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by SPRO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-06 | Debra Zack | Chief Medical Officer | A | +162,311 | — |
| 2026-06-25 | Milind Deshpande | Director | A | +10,000 | — |
| 2026-06-25 | Cynthia Smith | Director | A | +10,000 | — |
| 2026-06-25 | Kathleen Tregoning | Director | A | +10,000 | — |
| 2026-06-25 | John C Pottage Jr | Director | A | +10,000 | — |
| 2026-06-25 | Frank E Thomas | Director | A | +10,000 | — |
| 2026-06-25 | Scott Thomas Jackson | Director | A | +10,000 | — |
| 2026-06-25 | Patrick V.J.J. Vink | Director | A | +10,000 | — |
| 2026-05-06 | Esther Rajavelu | See Remarks | Sell | −25,240 | −$63.35K |
| 2026-02-09 | Timothy Keutzer | Chief Operating Officer | Sell | −18,652 | −$44.02K |
| 2026-02-09 | Esther Rajavelu | See Remarks | Sell | −87,917 | −$207.48K |
| 2026-02-05 | Timothy Keutzer | Chief Operating Officer | MIXED | +21,414 | −$101.17K |
| 2026-02-04 | Esther Rajavelu | See Remarks | MIXED | +230,558 | −$40.57K |
| 2025-11-12 | Esther Rajavelu | See Remarks | Sell | −40,270 | −$95.44K |
| 2025-09-03 | Ankit Mahadevia | Director | Sell | −6,572 | −$12.95K |
| 2025-09-03 | Timothy Keutzer | Chief Operating Officer | Sell | −1,695 | −$3.34K |
| 2025-06-16 | John C Pottage Jr | Director | A | +20,000 | — |
| 2025-06-16 | Patrick V.J.J. Vink | Director | A | +20,000 | — |
| 2025-06-16 | Scott Thomas Jackson | Director | A | +20,000 | — |
| 2025-06-16 | Milind Deshpande | Director | A | +20,000 | — |
| 2025-06-16 | Kathleen Tregoning | Director | A | +20,000 | — |
| 2025-06-16 | Cynthia Smith | Director | A | +20,000 | — |
| 2025-06-16 | Frank E Thomas | Director | A | +20,000 | — |
| 2025-06-16 | Ankit Mahadevia | Director | A | +20,000 | — |
| 2025-05-06 | Esther Rajavelu | See Remarks | A | +185,000 | — |
| 2025-02-05 | Esther Rajavelu | CFO & CBO | MIXED | +345,450 | −$16.14K |
| 2025-02-05 | Ankit Mahadevia | Director | Sell | −69,219 | −$53.99K |
| 2025-02-05 | Sath Shukla | CEO & President | MIXED | +596,074 | −$121.16K |
| 2025-02-05 | Timothy Keutzer | Chief Operating Officer | MIXED | +209,602 | −$44.10K |
| 2024-11-12 | Esther Rajavelu | CFO & CBO | Sell | −40,596 | −$53.01K |
| 2024-08-29 | Timothy Keutzer | Chief Operating Officer | Sell | −2,213 | −$2.99K |
| 2024-08-29 | Ankit Mahadevia | Director | Sell | −5,912 | −$7.98K |
| 2024-08-29 | Sath Shukla | CEO & President | Sell | −2,757 | −$3.72K |
| 2024-08-06 | Sath Shukla | CEO and President | Sell | −32,441 | −$42.65K |
| 2024-05-30 | Milind Deshpande | Director | A | +20,000 | — |
| 2024-05-30 | Cynthia Smith | Director | A | +20,000 | — |
| 2024-05-30 | Patrick V.J.J. Vink | Director | A | +20,000 | — |
| 2024-05-30 | Scott Thomas Jackson | Director | A | +20,000 | — |
| 2024-05-30 | Kathleen Tregoning | Director | A | +20,000 | — |
| 2024-05-30 | Frank E Thomas | Director | A | +20,000 | — |
| 2024-05-30 | Ankit Mahadevia | Director | A | +20,000 | — |
| 2024-05-30 | John C Pottage Jr | Director | A | +20,000 | — |
| 2024-02-05 | Esther Rajavelu | See Remarks | A | +119,866 | — |
| 2024-02-05 | Ankit Mahadevia | Director | Sell | −63,795 | −$87.40K |
| 2024-02-05 | Tamara L Joseph | Chief Legal Officer | MIXED | +208,825 | −$42.34K |
| 2024-02-05 | Sath Shukla | CEO and President | MIXED | +603,507 | −$107.72K |
| 2024-02-05 | Kamal Hamed | Chief Medical Officer | MIXED | +211,656 | −$38.46K |
| 2024-02-05 | Timothy Keutzer | Chief Operating Officer | MIXED | +208,760 | −$42.12K |
| 2024-01-04 | Kathleen Tregoning | Director | A | +35,604 deriv. | — |
| 2023-11-15 | Esther Rajavelu | See Remarks | A | +300,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sath Shukla | CEO & President | 1,892,216 | $2.03M |
| Esther Rajavelu | See Remarks | 986,851 | $1.06M |
| Timothy Keutzer | Chief Operating Officer | 742,506 | $798.19K |
| Ankit Mahadevia | Director | 703,294 | $756.04K |
| Debra Zack | Chief Medical Officer | 162,311 | $174.48K |
| Milind Deshpande | Director | 101,454 | $109.06K |
| Frank E Thomas | Director | 85,000 | $91.38K |
| John C Pottage Jr | Director | 85,000 | $91.38K |
| Patrick V.J.J. Vink | Director | 85,000 | $91.38K |
| Scott Thomas Jackson | Director | 85,000 | $91.38K |
| Cynthia Smith | Director | 85,000 | $91.38K |
| Kathleen Tregoning | Director | 85,000 | $91.38K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SPRO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.